NEW YORK (GenomeWeb) – Adoptees signing up for direct-to-consumer genomic testing services often hope to fill the gaps in their family health history and genetic disease risk profile, but they do not differ from nonadoptees in the way they use the results to improve their health, according to a new study by researchers at Brigham and Women's Hospital and Harvard Medical School.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.